Cameroon: Aids Vaccine: Doctor Cries Foul

By Musa, Tansa | New African, February 2004 | Go to article overview
Save to active project

Cameroon: Aids Vaccine: Doctor Cries Foul


Musa, Tansa, New African


When Professor Victor Anomah Ngu (above) announced in Yaounde in 2001 that he had developed an auto-vaccine therapy against HIV/Aids, his colleagues at home rubbished his claims. Now, he says an American company has taken his discovery. Tansa Musa reports.

**********

Three years after he had been laughed at by his colleagues at home, Prof Victor Ngu was comforted when the Emory University School of Medicine in the USA, showed interest last year in his work. The two went on to sign a confidentiality and collaboration agreement to pursue the research.

[ILLUSTRATION OMITTED]

But on 16 December 2003, Prof Ngu (a 1972 Albert Lasker Award winner in cancer research), alleged that the American company, Lipid Sciences Inc, borrowed his work and claimed it for itself. Ngu made the allegations in Yaounde 13 days after Lipid Sciences announced in Pleasanton, California, that it had completed successful studies in a mouse animal model.

The company described the studies as an important development milestone. It further said it was now initiating a series of non-human primate studies to further validate its "unique delipidation technology" with the ultimate goal of developing a therapeutic vaccine for use against HIV.

"Based on the excellent results we have seen in animal studies with mice, we have now moved our developmental programme forward to nonhuman primates. This step is consistent with our strategic plan and is the next step in the validation of our viral immunotherapy platform," noted Dr. S. Lewis Meyer, president and CEO of Lipid Sciences.

"The final results of these non-human primate studies will enable the company to present data to the FDA [Food and Drug Administration] and discuss what additional pre-clinical testing, if any, might need to be completed before we move into a human clinical trial," Meyer added.

Lipid Sciences is a development-stage company engaged in the research and development of products and processes to treat major medical conditions. The company's viral immunotherapy platform is focused on the removal of lipid coatings from viruses and other infectious agents by applications of its delipidation technology.

According to the company, removing the protective lipid coating of viruses exposes otherwise hidden proteins to stimulate the body's immune system and elicit an enhanced therapeutic response.

But the process shows striking similarity to Prof Ngu's discovery, presented to the public in Yaounde (Cameroon's capital) in 2001. Ngu's "Vanhivax" is prepared from the HIV present in his patients and administered to them as a vaccine. From trials, it has shown to cause a drop in the viral loads of patients and an increase in body weight and CD4 count.

Incidentally, Lipid Sciences' mouse studies were conducted under the direction of Dr Aftab Ansari, professor at the Department of Pathology and Laboratory Medicine at the Emory University's School of Medicine.

He is a member of the Lipid Sciences' viral advisory board. He was in Yaounde at the time Prof Ngu announced his ground-breaking discovery and negotiated the confidentiality and collaborative agreement between his institution and Ngu's team.

Speaking at the Pleasanton ceremony, Dr Ansari observed that Lipid Sciences had found "a unique, optimised treatment that is highly effective, not only in delipidation, but also in reducing viral infectivity while appearing to retain a very high percentage of significant viral proteins".

But according to Prof Ngu, the Lipid Sciences team, including Dr Ansari, invited itself to Cameroon after it had seen the preliminary results of his work presented at a Vaccines Conference in Keystones, Colorado, in January 2002, by Dr Boma, one of Ngu's assistants. It is this presentation that led the two teams to signing the confidentiality and collaborative agreement in April 2002.

In fact, while in Yaounde on 12 June 2002, Dr Ansari had hailed Prof Ngu's work.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Cameroon: Aids Vaccine: Doctor Cries Foul
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?